Ronald Bailey | July 28, 2006
That's the question asked by Massachusetts General Hospital endocrinologist David A. Shaywitz in an op/ed in the Boston Globe. To wit:
The national preoccupation with university researchers who collaborate with drug companies has now blossomed into a full-fledged witch hunt. Before we burn these heathen scientists at the stake, however, we might want to step back and examine our underlying assumptions. . . .
Ultimately, the myopic focus on financial conflicts is likely to discourage relationships between university researchers and drug companies--a bad idea, since these associations offer enormous potential for medical advancement.
Whole thing here.
Help Reason celebrate its next 40 years. Donate Now!
Try Reason's award-winning print edition today! Your first issue is FREE if you are not completely satisfied.
Site comments/questions:
Media Inquiries and Reprint Permissions:
(310) 367-6109
Editorial & Production Offices:
3415 S. Sepulveda Blvd.
Suite 400
Los Angeles, CA 90034
(310) 391-2245